Home
Company
Our Vision
Our Leadership Team
Naronapride (ATI-7505)
About Naronapride (ATI-7505)
Mechanism of Action
Development Status
Chemistry and Manufacturing
Regulatory Developments
Knowledge Centre
Gastrointestinal Dysmotility in Cystic Fibrosis (CF)
Gastroparesis
Chronic Idiopathic Constipation
Irritable Bowel Syndrome
PPI non-responsive GERD
Functional Dyspepsia
News
Press
>
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of naronapride in patients with gastroparesis
Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients
Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment
Renexxion Ireland Announces Issuance of a New US Patent covering Naronapride, a Clinical Stage Potential Best-in-Class Prokinetic Agent for Gastrointestinal Disorders
Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH
Contact
Our Leadership Team
Our leadership team is composed of biotech industry veterans with many years of experience in all areas of pharmaceutical drug development, management and financing.
Peter G. Milner
MD, FACC
Co-founder, Director, and Chief Executive Officer
More...
Pascal Druzgala
PhD
Co-founder, Director, and Chief Scientific Officer
More...
M. (Ken) Kengatharan
PhD, MBA
Co-founder, Director, and Chief Business Officer
More...
Ivan Coulter
PhD, MBA
Director
More...
Richard Hendrick
Director
More...
Catherine Pearson
Chief Executive Officer
More...
Mark Midei
Chief Medical Officer
More...
Elizabeth Ahrens
JD -
Coroporate Counsel
More...
Home
Company
Our Vision
Our Leadership Team
Naronapride (ATI-7505)
About Naronapride (ATI-7505)
Mechanism of Action
Development Status
Chemistry and Manufacturing
Regulatory Developments
Knowledge Centre
Gastrointestinal Dysmotility in Cystic Fibrosis (CF)
Gastroparesis
Chronic Idiopathic Constipation
Irritable Bowel Syndrome
PPI non-responsive GERD
Functional Dyspepsia
News
Press
>
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of naronapride in patients with gastroparesis
Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients
Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment
Renexxion Ireland Announces Issuance of a New US Patent covering Naronapride, a Clinical Stage Potential Best-in-Class Prokinetic Agent for Gastrointestinal Disorders
Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH
Contact